Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077893 · ClinicalTrials.gov registry record · NA
Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy
A NA study of Diabetic Peripheral Neuropathy, sponsored by Regenesis Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT03077893: Completed NA study of Diabetic Peripheral Neuropathy, sponsored by Regenesis Biomedical.
NCT03077893 is a NA study of Diabetic Peripheral Neuropathy that has completed, run by Regenesis Biomedical. The registered enrollment target is 44 participants, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03077893, a NA study of Diabetic Peripheral Neuropathy, has completed, sponsored by Regenesis Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.
Primary Outcome
A non-invasive test used in quantifying sensation/sensitivity to vibration in evaluating sensory dysfunction associated with diabetic neuropathy
Conditions Studied
Interventions
- DEVICE Active Provant Therapy System
- DEVICE Inactive (sham) Provant Therapy System
Study Locations (1)
Arizona
- Associated Foot & Ankle Specialists, LLC - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2017-12-26 |
| Phase | NA |
What the finished NCT03077893 record still lists
NCT03077893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Active Provant Therapy System is the first listed.
NCT03077893 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03077893 about?
NCT03077893 is a clinical study titled "Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy". A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.
What is the current status of trial NCT03077893?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2017-03-09. Estimated completion is 2017-12-26.
What conditions does trial NCT03077893 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy.
What interventions are being tested in trial NCT03077893?
The interventions under investigation include: Active Provant Therapy System (DEVICE), Inactive (sham) Provant Therapy System (DEVICE).
Who is sponsoring clinical trial NCT03077893?
This trial is sponsored by Regenesis Biomedical, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03077893 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03077893's enrollment target sits among peer trials
44 12th of 17 higher than 4 of 17 other Diabetic Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Walking Function in Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
RECRUITING · NA
-
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Balance Control and Recovery in Diabetes Peripheral Neuropathy
RECRUITING · NA
-
Corneal Nerves Function and Structure
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI